Endometrial cancer · 6 regimens
Cost vs Efficacy · 2 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Medroxyprogesterone acetate monotherapy Variant #01 | — | R 1 178 | 28d | — | ~6.0 mo | — | — | 1 |
Medroxyprogesterone acetate and Tamoxifen Variant #01 | — | R 509 | 28d | — | — | — | — | — |
Tamoxifen monotherapy Variant #06 | — | R 410 | 28d | ~7.2 mo | — | ~8 | ~R 3 279 PFS proxy · indirect | 1 |
Megestrol and Tamoxifen Variant #01 Partial | — | R 205 | 21d | — | — | — | — | — |
Anastrozole monotherapy Variant #01 | — | R 159 | 28d | ~13.8 mo | ~42.7 mo | ~16 | ~R 2 546 PFS proxy · indirect | 12 |
Megestrol monotherapy Variant #01 Partial | — | — | 28d | — | — | — | — | — |
6 of 6 regimens shown